2025-2034 Fabry Disease Market Roadmap: Insights for Competitive Advantage

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Fabry Disease Market Size By 2025?
Recently there has been significant growth in the fabry disease market size. Expected to rise from $2.1 billion in 2024 to $2.26 billion in 2025, the market possesses a compound annual growth rate (CAGR) of 7.2%. This growth during the historic period stems from factors such as heightened awareness and identification of rare diseases, the expansion of specialized healthcare facilities, government support and orphan drug commendations, rising funding dedicated to rare disease research, as well as the commencement of new therapy launches.

How Big Is the Fabry Disease Market Size Expected to Grow by 2029?
There is an anticipation for considerable expansion in the Fabry disease market size in the forthcoming years. The market is predicted to rise to "$3.04 billion by 2029" with a compound annual growth rate (CAGR) of 7.7%. This predicted growth within the forecast period can be linked to factors such as the broadening of newborn screening initiatives, governmental backing for orphan and rare condition medications, enhanced access to healthcare, advances in telemedicine and remote treatment, and an increasing preference for customised healthcare. The forecast period is also expected to see major trends, including increased usage of enzyme replacement therapy, progress in genetic testing, incorporation of AI and digital tools for early detection, AI-driven diagnostic algorithms, and advancements in gene therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

Which Key Market Drivers Powering Fabry Disease Market Expansion and Growth?
The emphasis on personalized medicine, designed around an individual's genetic makeup, environment, and lifestyle, is projected to fuel the expansion of the fabry disease market. Personalized medicine's rise is primarily because of its potential to enhance treatment efficacy and reduce unwanted side effects by customizing therapies to each patient's unique needs. The approach fine-tunes treatment plans by accounting for a patient's genetic mutation and degree of disease severity, enhancing results while mitigating unnecessary side effects. To illustrate, the Personalized Medicine Coalition, a nonprofit organization in the US, was involved in the approval of 16 new personalized treatments for rare disease patients by the FDA in 2023, a significant upswing from just six approvals in the previous year, 2022. Therefore, an increasing emphasis on personalized medicine is propelling the growth of the fabry disease market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Fabry Disease Market?
Key players in the fabry disease market are concentrating their efforts on devising innovative therapies like PEGylated enzyme replacement therapy (ERT) with an aim to boost treatment effectiveness, enhance patient adherence, and mitigate immunogenic responses tied to conventional ERTs. This novel type of ERT has been modified by attaching polyethylene glycol (PEG) chains to the enzyme, thereby enhancing its stability, prolonging its circulation time in the body, and curtailing immune system responses. In a related development in May 2023, Chiesi Global Rare Diseases, a branch of the Italy-based Chiesi Group, reported that their treatment, PRX-102 (pegunigalsidase alfa), for adult Fabry disease patients got the green light from the U.S. Food and Drug Administration (FDA). The accord was based on a sturdy clinical programme that involved more than 140 patients and long-haul follow-up spanning up to 7.5 years, which manifested the therapy's efficacy in curbing renal Gb3 deposits, preserving kidney functionality while presenting a propitious safety track record.

What Are the Emerging Segments in the Fabry Disease Market?
The fabry disease market covered in this report is segmented -

1) By Type: Type 1, Type 2, Other Types
2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments
3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease
2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease
3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp

Who Are the Global Leaders in the Fabry Disease Market?
Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Which are the Top Profitable Regional Markets for the Fabry Disease Industry?
North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24218

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.